Clinical Trials Logo

Giant Cell Tumors clinical trials

View clinical trials related to Giant Cell Tumors.

Filter by:

NCT ID: NCT02371369 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

ENLIVEN
Start date: May 11, 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good. The main purpose of this study is to gather information about the investigational drug pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS). The study consists of two parts with a follow-up period. In Part 1, eligible study participants will be assigned to receive either pexidartinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Some subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2. Then a protocol amendment was written to allow only pexidartinib patients to continue into Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label pexidartinib. There was also a follow-up period added to Part 2.

NCT ID: NCT01643850 Completed - Clinical trials for Pigmented Villonodular Synovitis

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Start date: April 23, 2012
Phase: Phase 2
Study type: Interventional

This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) patients, after a single or multiple intravenous doses of MCS110, using magnetic resonance imaging to assess tumor volume, and evaluated the pharmacokinetics/pharmacodynamics, safety and tolerability in this population.

NCT ID: NCT01261429 Completed - Clinical trials for Pigmented Villonodular Synovitis

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by surgery. The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery. this study is an international, multicentre, non-randomized, open-label phase II clinical trial with a Bayesian design. A maximum sample size of 50 patients will be included in the study

NCT ID: NCT00680992 Completed - Cancer Clinical Trials

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Start date: September 9, 2008
Phase: Phase 2
Study type: Interventional

To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)

NCT ID: NCT00464620 Completed - Rhabdomyosarcoma Clinical Trials

Trial of Dasatinib in Advanced Sarcomas

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

NCT ID: NCT00396279 Completed - Clinical trials for Giant Cell Tumor of Bone

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Start date: July 10, 2006
Phase: Phase 2
Study type: Interventional

To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.